Advancing Bioconjugate Development Through Platform-Based Analytics

Bioconjugates are becoming an important part of the oncology pipeline, combining targeted delivery with highly potent payloads. As the field has advanced, bioconjugate formats have diversified to incorporate new conjugation strategies, linker chemistries, and payload classes.

This growing molecular complexity, combined with shorter development timelines, is adding pressure on analytical teams to characterize antibody-drug conjugates (ADCs) efficiently without compromising robustness or regulatory readiness.

This article discusses how platform-based analytical development can provide an established but adaptable framework to streamline characterization, improve reproducibility across programs, and support greater continuity from early development into manufacturing.

Analytical bottlenecks slowing bioconjugate development

Bioconjugates combine selective target binding with potent cytotoxic activity. This dual mechanism creates a broader analytical burden than conventional biologics. Developers must characterize the antibody, linker, and payload individually while also determining how conjugation affects the quality and performance of the final molecule.

Alongside conventional measures such as identity, purity, size, charge, and stability, bioconjugate programs require the assessment of several attributes unique to these hybrid molecules. Of particular importance is the drug-to-antibody ratio (DAR), which must be measured accurately throughout development because it can affect efficacy, stability, and safety.

Teams must also monitor free drug and linker-payload-related species, process-related impurities such as residual solvents, and mechanism-relevant potency. Because these attributes can change during process development, scale-up, and storage, analytical methods must be robust and reproducible, capable of detecting and distinguishing meaningful shifts within a heterogeneous product.

The absence of suitable early-stage methods can become a significant bottleneck, delaying wider program decisions or forcing activities to proceed with analytical uncertainty. If methods require substantial development, optimization, or rework before they can generate reliable results, activities may be delayed or proceed with greater uncertainty.

As projects progress, analytical demands continue to evolve, with the potential to create further bottlenecks:

• Scale-up and process development. Scale-up can alter DAR distributions, impurity levels, and other critical quality attributes (CQAs), requiring methods to remain suitable as materials and process conditions change. Site-specific conjugation may also introduce enzymes or small-molecule reagents that must be monitored and removed, although emerging bioconjugate modalities may require techniques that differ from those used for conventional cysteine- or lysine-linked ADCs.
• Regulatory pressure. On top of evolving technical requirements, developers must also navigate increasingly stringent regulatory expectations and compressed development timelines as projects progress. Regulators expect early, data-driven evidence supporting CQAs and product consistency, leaving limited scope for analytical uncertainty. Analytical gaps identified late in development can lead to method redevelopment, additional stability work, repeated testing, or delays to submission of an Investigational New Drug application.

Early analytical insight is therefore essential to de-risking development and maintaining momentum from discovery through to clinical manufacturing. Without this analytical foundation, uncertainty accumulates across the program and increases the likelihood of rework and missed development milestones.

Why platform-based analytical approaches are gaining traction

Platform-based analytical approaches are attracting greater interest as a way of reducing the time and uncertainty involved in establishing suitable methods for each new bioconjugate program. A proven analytical foundation that can be adapted to individual molecules lets development teams generate reliable data earlier and keeps characterization delays from slowing down wider development work.

Building on established analytical foundations

A key advantage of platform-based development is the ability to draw on methods and analytical data generated across multiple bioconjugate formats, conjugation chemistries, linker-payload combinations, and impurity profiles. Platform-based approaches provide a common analytical framework that can be applied across multiple formats and conjugation strategies.

Early feasibility assessments help identify which methods are suitable and in which refinement may be required, reducing the likelihood of late-stage changes and supporting more predictable development timelines. By building on established analytical frameworks, developers can focus resources on targeted optimization instead of repeatedly creating methods from scratch.

Preserving flexibility across diverse bioconjugate formats

A platform approach does not mean that identical analytical methods are used for every molecule. Differences in physicochemical properties, conjugation chemistries, and impurity profiles mean that no single fixed method set can adequately characterize every bioconjugate.

Instead, platform-based development combines standardized frameworks with targeted customization, allowing methods to be adapted according to the requirements of individual molecules and emerging modalities. Analytical approaches used for random bioconjugation may need to be modified for site-specific products, although emerging modalities may require different techniques altogether.

Building this flexibility into the platform allows developers to retain the speed and reproducibility of an established approach while ensuring that characterization remains appropriate for the individual product.

Maintaining development momentum

Once teams identify and adapt suitable methods to the individual bioconjugate, they can generate reliable analytical data earlier in development. This allows process, formulation, and analytical activities to progress in parallel, rather than waiting for characterization issues to be resolved later in the program.

By combining early method selection with targeted optimization, platform-based approaches create greater continuity across the development program, which supports more predictable progression toward regulatory submission.

Supporting scalability and smoother progression into manufacturing

The value of a platform-based approach continues as a bioconjugate program moves beyond early analytical development. Teams can optimize, qualify, and document methods established within a common framework through a consistent process, creating greater continuity as testing moves from development laboratories into quality control and Good Manufacturing Practice (GMP) environments.

This continuity is particularly important during scale-up. Analytical methods must continue to monitor CQAs and detect low-level product and process-related impurities as manufacturing conditions and material volumes change.

Platform-based solutions provide established approaches for attributes such as DAR, free drug and linker-payload species, residual solvents, and potency, while retaining the flexibility to adjust individual methods to the characteristics of the molecule. Once a team selects and adapts a method for the individual bioconjugate, it conducts preliminary qualification to demonstrate that the method performs reliably for its intended use.

The resulting method reports and standard operating procedures capture how the assay should be run and how its performance has been demonstrated. This gives quality control laboratories a clearer basis for implementing the method and can reduce the risk of transfer-related issues.

A shared analytical framework can also connect analytical, process, and manufacturing activities more closely. Teams work from a consistent understanding of the product’s CQAs, supporting more coordinated troubleshooting and continued product control as programs progress into release and stability testing for toxicology and clinical batches.

Platform-based approaches therefore provide the analytical consistency, transferability, and adaptability needed to move bioconjugate programs through scale-up and into clinical manufacturing with fewer disruptions.

How integrated analytical capabilities accelerate development

The value of platform-based methods depends heavily on the expertise with which they are applied. Effective bioconjugate characterization requires expertise that spans biologics, small-molecule chemistry, and potency testing—disciplines that must be interpreted together, not in isolation.

Bringing these capabilities together allows analytical results to be interpreted within the wider context of the molecule and its manufacturing process. This supports more coordinated decision-making, accelerates troubleshooting, and helps teams focus optimization on the attributes most relevant to product quality.

Integrated expertise is also essential to applying platform methods appropriately, helping determine which established approaches are suitable for the individual use case, which conditions require refinement, and when a different analytical technique is needed. This approach is particularly useful for emerging bioconjugate modalities, such as antibody-oligonucleotide conjugates, which can introduce analytical requirements that differ from those of conventional bioconjugates.

For example, charge-based methods such as anion exchange chromatography can be particularly effective for resolving species with different oligonucleotide-to-antibody ratios, whereas hydrophobic interaction chromatography and reversed-phase high-performance liquid chromatography are more commonly used to characterize conventional cysteine- or lysine-linked ADCs.

This coordinated approach allows analytical strategies to be aligned with the product’s physicochemical properties, conjugation modality, therapeutic goals, and regulatory pathway while keeping common development frameworks efficient.

These capabilities may be built internally or accessed through an external development and manufacturing partner. In either case, integrating the relevant analytical disciplines helps translate platform methods into faster decisions, targeted method development, and more consistent progression from early characterization into manufacturing.

Building a more predictable path to manufacturing

As bioconjugate formats continue to diversify, analytical development must deliver reliable insight without slowing wider program progression. Platform-based approaches help address this challenge by providing established methods and workflows that can be adapted to the specific characteristics of each molecule.

Early feasibility assessments and targeted optimization can reduce repeated method development, support more consistent data generation, and allow process and formulation activities to progress with greater confidence. As programs advance, the same analytical foundation can also improve method transfer and maintain continuity through scale-up, GMP testing, and clinical manufacturing.

The value of platform-based approaches lies in combining standardization with flexibility. Supported by integrated analytical expertise, this approach can help developers manage increasing bioconjugate complexity while improving predictability from early characterization through to manufacturing.

About the Author

Myunghee Song is director of ADC Analytical Development at Samsung Biologics.